Skip to main content
. 2019 Apr 2;18:111. doi: 10.1186/s12936-019-2745-7

Table 2.

Frequency of outcomes of interest by primaquine dose category

No PQ LDP HDP LDP or HDP versus no PQ
n/N (%) n/N (%) n/N (%) OR (95%CI)
1–6 m
 Severe anaemiaa 10/246 (4.1) 0/0 (–) 0/0 (–)
 Hb fall > 25% to < 5 g/dL 4/183 (2.2) 0/0 (–) 0/0 (–)
 Admission 3–30 d 118/1208 (9.8) 0/2 (0) 0/13 (0)
 Death 3–30 d 11/1208 (0.91) 0/2 (0) 0/13 (0)
6–12 m
 Severe anaemiaa 21/451 (4.7) 0/6 (0) 5/27 (18.5) 3.66 (1.28–10.4)
 Hb fall > 25% to < 5 g/dL 12/278 (4.3) 0/4 (0) 1/19 (5.3) 1.01 (0.13–8.11)
 Admission 3–30 d 178/2224 (8.0) 3/31 (9.7) 9/161 (5.6) 0.77 (0.42–1.40)
 Death 3–30 d 6/2224 (0.27) 1/31 (3.2) 2/161 (1.2) 5.87 (1.46–23.6)
1–12 m
 Severe anaemiaa 31/697 (4.5) 0/6 (0) 5/27 (18.5) 3.84 (1.39–10.6)
 Hb fall > 25% to < 5 g/dL 16/461 (3.5) 0/4 (0) 1/19 (5.3) 1.26 (0.16–9.97)
 Admission 3–30 d 296/3432 (8.6) 3/33 (9.1) 9/174 (5.2) 0.65 (0.36–1.18)
 Death 3–30 d 17/3432 (0.50) 1/33 (3.0) 2/174 (1.2) 2.95 (0.86–10.2)

PQ primaquine, LDP low dose primaquine, HDP high dose primaquine, n number with outcome, N denominator, OR odds ratio, 95% CI 95% confidence interval, Hb haemoglobin, m months, d day

aLimited to infants who were not severely anaemic at baseline